MERTK and neoplasm: CD8+ T cells restrict the metastatic growth of cancer cells from the primary tumor; when MERTK, a tyrosine kinase receptor that inhibits NK cells activation, is inhibited, NK cells have the ability to reject metastatic tumor cells [109,110].